Citations

Clear

382 citation(s) found for "Li, Man".

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series
Shankar, Sudha S. , Raymond, Ralph, Staten, Myrlene A. , Calle, Roberto A. , Bergman, Richard N. , Cao, Charlie, Man, Chiara Dalla , Deeg, Mark A. , Dong, Jennifer , Polidori, David , Robertson, R. Paul , Ruetten, Hartmut, Stefanovski, Darko , Vassileva, Maria T. , Weir, Gordon C. , Vella, Adrian , Chen, Danny, Cobelli, Claudio , Lee, Douglas S. , Fryburg, David A. , Dalla Man, Chiara

Mayo Clinic

Diabetes Care | July 13, 2016 | Volume: 39 | Issue: 9 | Pages: 1602-1613

10.2337/dc15-0931 | PMID 27407117 Get It

OBJECTIVE Standardized, reproducible, and feasible quantification of β-cell function (BCF) is necessary for the evaluation of interventions to improve insulin secretion and important for comparison across studies. We therefore characterized the responses to, and reproducibility of, standardized methods of in vivo BCF across different glucose tolerance states. RESEARCH DESIGN AND METHODS Participants classified as having normal glucose tolerance (NGT; n = 23), prediabetes (PDM; n = 17), and type 2 diabetes mellitus (T2DM; n = 22) underwent two standardized mixed-meal tolerance tests (MMTT) and two standardized arginine stimulation tests (AST) in a test-retest paradigm and one frequently sampled intravenous glucose tolerance test (FSIGT). RESULTS From the MMTT, insulin secretion in T2DM was >86% lower compared with NGT or PDM (P < 0.001). Insulin sensitivity (Si) decreased from NGT to PDM (∼50%) to T2DM (93% lower [P < 0.001]). In the AST, insulin secretory response to arginine at basal glucose and during hyperglycemia was lower in T2DM compared with NGT and PDM (>58%; all P < 0.001). FSIGT showed decreases in both insulin secretion and Si across populations (P < 0.001), although Si did not differ significantly between PDM and T2DM populations. Reproducibility was generally good for the MMTT, with intraclass correlation coefficients (ICCs) ranging from ∼0.3 to ∼0.8 depending on population and variable. Reproducibility for the AST was very good, with ICC values >0.8 across all variables and populations. CONCLUSIONS Standardized MMTT and AST provide reproducible and complementary measures of BCF with characteristics favorable for longitudinal interventional trials use.
In Silico Optimization of Basal Insulin Infusion Rate during Exercise: Implication for Artificial Pancreas
Schiavon, Michele , Man, Chiara Dalla , Kudva, Yogish C. , Basu, Ananda , Cobelli, Claudio , Dalla Man, Chiara , Schiavon, Michele

Mayo Clinic

Journal of Diabetes Science and Technology | June 6, 2016 | Volume: 7 | Issue: 6 | Pages: 1461-1469

10.1177/193229681300700606 | PMID 24351172 Get It

Background: Several clinical trials have been performed to assess safety and efficacy of closed-loop control. Some included physical activity (PA), with the goal of challenging the control algorithms with a rapid change in insulin sensitivity while reducing the risk of hypoglycemia. However, the question remains as to the necessity to inform the control algorithm on the imminent PA. The aim here is to assess in silico (i) if it is necessary to announce upcoming PA and (ii) if this is the case, what is the safest strategy of basal insulin reduction in the context of the closed-loop control. Methods: We modified the University of Virginia/Padova type 1 diabetes simulator to incorporate the effect of PA based on a study in healthy subjects that demonstrated an almost doubling of insulin sensitivity during PA versus rest. Two in silico experiments, including a PA session, have been simulated on the virtual adult population: One in the absence of and one with different degrees of reductions and durations of basal insulin infusion rates. Results: Most in silico subjects experienced hypoglycemia in the absence of basal insulin adjustment. We show that, in the absence of patient-specific information, a safe and effective strategy is to reduce basal insulin by 50% starting 90 min before exercise and by 30% during exercise. Conclusions: Our results suggest that control algorithms could benefit by knowing an upcoming PA. Ideally, the control algorithm should be informed about the patient-specific basal insulin reduction pattern. An alternative strategy that has been proposed here has been deemed safe and effective in in silico experiments.
Interstitial Fluid Glucose Is Not Just a Shifted-in-Time but a Distorted Mirror of Blood Glucose: Insight from an In Silico Study
Schiavon, Michele , Man, Chiara Dalla , Basu, Ananda , Basu, Rita , Cobelli, Claudio , Dalla Man, Chiara , Schiavon, Michele

Mayo Clinic

Diabetes Technology & Therapeutics | June 2, 2016 | Volume: 18 | Issue: 8 | Pages: 505-511

10.1089/dia.2016.0112 | PMID 27253751 Get It

Background: Glucose sensors measure glucose concentration in the interstitial fluid (ISF), remote from blood. ISF glucose is well known to be “delayed” with respect to blood glucose (BG). However, ISF glucose is not simply a shifted-in-time version of BG but exhibits a more complex pattern. Methods: To gain insight into this problem, one can use linear systems theory. However, this may lose a more clinical readership, thus we use simulation and two case studies to convey our thinking in an easier way. In particular, we consider BG concentration measured after meal and exercise in 12 healthy volunteers, whereas ISF glucose is simulated using a well-accepted model of blood–ISF glucose kinetics, which permits calculation of the equilibration time, a parameter characterizing the system. Two metrics are defined: blood and ISF glucose difference at each time point and time to reach the same glucose value in blood and ISF. Results: The simulation performed and the two metrics show that the relationship between blood–ISF glucose profiles is more complex than a pure shift in time and that the pattern depends on both equilibration time and BG. Conclusions: In this in silico study, we have illustrated, with simple case studies, the meaning of the of ISF glucose with respect to BG. Understanding that ISF glucose is not just a shifted-in-time version but a distorted mirror of BG is important for a correct use of continuous glucose monitoring for diabetes management.
Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice
Ho, Ada Man‐Choi , Qiu, Yanyan, Jia, Yun‐Fang , Aguiar, Felipe S., Hinton, David J., Karpyak, Victor M. , Weinshilboum, Richard M. , Qiu, Yanyan, Weinshilboum, Richard M. , Choi, Doo‐Sup , Ho, Ada M-C , Karpyak, Victor

Mayo Clinic

Alcoholism: Clinical and Experimental Research | May 17, 2016 | Volume: 40 | Issue: 7 | Pages: 1531-1539

10.1111/acer.13099 | PMID 27184383 Get It

Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia
Parry, Helen , Damery, Sarah , Pachnio, Annette, Begum, Jusnara , Fegan, Chris , Man, Stephen , Pepper, Chris , Pratt, Guy , Moss, Paul , Hudson, Chris David , Maurer, Matthew J. , Cerhan, James R. , Slager, Susan L. , Shanafelt, Tait D.

Mayo Clinic

American Journal of Hematology | April 30, 2016 | Volume: 91 | Issue: 8 | Pages: 776-781

10.1002/ajh.24403 | PMID 27124884 Get It

Human cytomegalovirus (HCMV) is a widely prevalent herpes virus which establishes a state of chronic infection. The establishment of CMV‐specific immunity controls viral reactivation and leads to the accumulation of very large numbers of virus‐specific T cells which come to dominate the immune repertoire. There is concern that this may reduce the immune response to heterologous infections and HCMV infection has been associated with reduced survival in elderly people. Patients with chronic lymphocytic leukemia (B‐CLL) suffer from a state of immune suppression but have a paradoxical increase in the magnitude of the CMV‐specific T cell and humoral immune response. As such, there is now considerable interest in how CMV infection impacts on the clinical outcome of patients with B‐CLL. Utilizing a large prospective cohort of patients with B‐CLL (n = 347) we evaluated the relationship between HCMV seropositivity and patient outcome. HCMV seropositive patients had significantly worse overall survival than HCMV negative patients in univariate analysis (HR = 2.28, 95% CI: 1.34–3.88; P = 0.002). However, CMV seropositive patients were 4 years older than seronegative donors and this survival difference was lost in multivariate modeling adjusted for age and other validated prognostic markers (P = 0.34). No significant difference was found in multivariate modeling between HCMV positive and negative patients in relation to the time to first treatment (HR = 1.12, 95% CI: 0.68–1.84; P = 0.65). These findings in a second independent cohort of 236 B‐CLL patients were validated. In conclusion no evidence that HCMV impacts on the clinical outcome of patients with B‐CLL was found. Am. J. Hematol. 91:776–781, 2016. © 2016 Wiley Periodicals, Inc.
A Young Man With Progressive Language Difficulty and Early-Onset Dementia
Botha, Hugo , Jones, Lyell K. , Parisi, Joseph E. , Klaas, James P. , Boeve, Bradley F. , Jones, Lyell K , Botha, Hugo

Mayo Clinic

JAMA Neurology | March 28, 2016 | Volume: 73 | Issue: 5 | Pages: 595

10.1001/jamaneurol.2016.0246 | PMID 27019131 Get It

Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes
Hinshaw, Ling , Schiavon, Michele , Dadlani, Vikash, Mallad, Ashwini , Man, Chiara Dalla , Bharucha, Adil E. , Basu, Rita , Geske, Jennifer R. , Carter, Rickey E. , Basu, Ananda , Kudva, Yogish C. , Dalla Man, Chiara, Bharucha, Adil, Cobelli, Claudio , Dalla Man, Chiara , Carter, Rickey E , Geske, Jennifer , Schiavon, Michele

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 1, 2016 | Volume: 101 | Issue: 5 | Pages: 1954-1962

10.1210/jc.2015-3952 | PMID 26930181 Get It

Abstract Context: Early postprandial hyperglycemia and delayed hypoglycemia remain major problems in current management of type 1 diabetes (T1D). Objective: Our objective was to investigate the effects of pramlintide, known to suppress glucagon and delay gastric emptying, on postprandial glucose fluxes in T1D. Design: This was a single-center, inpatient, randomized, crossover study. Patients: Twelve patients with T1D who completed the study were analyzed. Interventions: Subjects were studied on two occasions with or without pramlintide. Triple tracer mixed-meal method and oral minimal model were used to estimate postprandial glucose turnover and insulin sensitivity (SI). Integrated liver insulin sensitivity was calculated based on glucose turnover. Plasma glucagon and insulin were measured. Main Outcome Measure: Glucose turnover and SI were the main outcome measures. Results: With pramlintide, 2-hour postprandial glucose, insulin, glucagon, glucose turnover, and SI indices showed: plasma glucose excursions were reduced (difference in incremental area under the curve [iAUC], 444.0 mMmin, P = .0003); plasma insulin concentrations were lower (difference in iAUC, 7642.0 pMmin; P = .0099); plasma glucagon excursions were lower (difference in iAUC, 1730.6 pg/mlmin; P = .0147); meal rate of glucose appearance was lower (difference in iAUC: 1196.2 μM/kg fat free mass [FFM]; P = .0316), endogenous glucose production was not different (difference in iAUC: −105.5 μM/kg FFM; P = .5842), rate of glucose disappearance was lower (difference in iAUC: 1494.2 μM/kg FFM; P = .0083). SI and liver insulin sensitivity were not different between study visits (P > .05). Conclusions: Inhibition of glucagon and gastric emptying delaying reduced 2-hour prandial glucose excursions in T1D by delaying meal rate of glucose appearance.
FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science
Alvin, C. H. , McNulty, Melissa S. , Poshusta, Tanya L., Campbell, Jarryd M. , Martínez‐Gálvez, Gabriel , Argue, David P., Lee, Han , Urban, Mark D. , Bullard, Cassandra E., Blackburn, Patrick R. , Man, Toni Ki Fong, Clark, Karl J. , Ekker, Stephen C. , Ma, Alvin C, Lee, Han B, Ekker, Stephen C , Lee, Han B , Clark, Karl J

Mayo Clinic

Human Gene Therapy | February 8, 2016 | Volume: 27 | Issue: 6 | Pages: 451-463

10.1089/hum.2015.172 | PMID 26854857 Get It

Transcription activator-like effectors (TALEs) are extremely effective, single-molecule DNA-targeting molecular cursors used for locus-specific genome science applications, including high-precision molecular medicine and other genome engineering applications. TALEs are used in genome engineering for locus-specific DNA editing and imaging, as artificial transcriptional activators and repressors, and for targeted epigenetic modification. TALEs as nucleases (TALENs) are effective editing tools and offer high binding specificity and fewer sequence constraints toward the targeted genome than other custom nuclease systems. One bottleneck of broader TALE use is reagent accessibility. For example, one commonly deployed method uses a multitube, 5-day assembly protocol. Here we describe FusX, a streamlined Golden Gate TALE assembly system that (1) is backward compatible with popular TALE backbones, (2) is functionalized as a single-tube 3-day TALE assembly process, (3) requires only commonly used basic molecular biology reagents, and (4) is cost-effective. More than 100 TALEN pairs have been successfully assembled using FusX, and 27 pairs were quantitatively tested in zebrafish, with each showing high somatic and germline activity. Furthermore, this assembly system is flexible and is compatible with standard molecular biology laboratory tools, but can be scaled with automated laboratory support. To demonstrate, we use a highly accessible and commercially available liquid-handling robot to rapidly and accurately assemble TALEs using the FusX TALE toolkit. Together, the FusX system accelerates TALE-based genomic science applications from basic science screening work for functional genomics testing and molecular medicine applications.
Model-Based Quantification of Glucagon-Like Peptide-1–Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge
Man, Chiara Dalla , Micheletto, Francesco, Sathananthan, Matheni, Vella, Adrian , Cobelli, Claudio , Dalla Man, Chiara

Mayo Clinic

Diabetes Technology & Therapeutics | January 12, 2016 | Volume: 18 | Issue: 1 | Pages: 39-46

10.1089/dia.2015.0146 | PMID 26756104 Get It

Background: Glucagon-like peptide-1 (GLP-1) is a powerful insulin secretagogue that is secreted in response to meal ingestion. The ability to quantify the effect of GLP-1 on insulin secretion could provide insights into the pathogenesis and treatment of diabetes. We used a modification of a model of GLP-1 action on insulin secretion using data from a hyperglycemic clamp with concomitant GLP-1 infusion. We tested this model using data from a mixed meal test (MMT), thereby measuring GLP-1-induced potentiation of insulin secretion in response to a meal. Materials and Methods: The GLP-1 model is based on the oral C-peptide minimal model and assumes that over-basal insulin secretion depends linearly on GLP-1 concentration through the parameter Π, representing the β-cell sensitivity to GLP-1. The model was tested on 62 subjects across the spectrum of glucose tolerance (age, 53 ± 1 years; body mass index, 29.7 ± 0.6 kg/m 2 ) studied with an MMT and provided a precise estimate of both β-cell responsivity and Π indices. By combining Π with a measure of L-cell responsivity to glucose, one obtains a potentiation index (PI) (i.e., a measure of the L-cell's function in relation to prevailing β-cell sensitivity to GLP-1). Results: Model-based measurement of GLP-1-induced insulin secretion demonstrates that the PI is significantly reduced in people with impaired glucose tolerance, compared with those with normal glucose tolerance. Conclusions: We describe a model that can quantitate the GLP-1-based contribution to insulin secretion in response to meal ingestion. This methodology will allow a better understanding of β-cell function at various stages of glucose tolerance.
TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes
Varghese, Ron T. , Miles, John M., Piccinini, Francesca, Man, Chiara Dalla , Bailey, Kent R. , Rizza, Robert A., Shah, Mithun V , Miles, John M., Cobelli, Claudio , Vella, Adrian , Dalla Man, Chiara

Mayo Clinic

Diabetes | November 3, 2015 | Volume: 65 | Issue: 2 | Pages: 371-380

10.2337/db15-1233 | PMID 26525881 Get It

The diabetes-associated allele in TCF7L2 increases the rate of conversion to diabetes; however, the mechanism by which this occurs remains elusive. We hypothesized that the diabetes-associated allele in this locus (rs7903146) impairs insulin secretion and that this defect would be exacerbated by acute free fatty acid (FFA)–induced insulin resistance. We studied 120 individuals of whom one-half were homozygous for the diabetes-associated allele TT at rs7903146 and one-half were homozygous for the protective allele CC. After a screening examination during which glucose tolerance status was determined, subjects were studied on two occasions in random order while undergoing an oral challenge. During one study day, FFA was elevated by infusion of Intralipid plus heparin. On the other study day, subjects received the same amount of glycerol as present in the Intralipid infusion. β-Cell responsivity indices were estimated with the oral C-peptide minimal model. We report that β-cell responsivity was slightly impaired in the TT genotype group. Moreover, the hyperbolic relationship between insulin secretion and β-cell responsivity differed significantly between genotypes. Subjects also exhibited impaired suppression of glucagon after an oral challenge. These data imply that a genetic variant harbored within the TCF7L2 locus impairs glucose tolerance through effects on glucagon as well as on insulin secretion.